

SCHIZOPHRENIA Factsheet

April 2022

What is prevalence?

Prevalence measures the proportion of individuals who have a disorder at a particular point in time (point prevalence) or during a specified period (annual prevalence, lifetime prevalence) and this may vary across regions. It is distinct from incidence, which refers to how many new cases there are per population in a specified time period. Lifetime prevalence is the number of individuals in a population that at some point in their life have experienced schizophrenia compared to the total number of individuals.

What is the evidence regarding prevalence of schizophrenia in migrant populations?

Moderate quality evidence found increased prevalence of schizophrenia in migrant groups compared to native-born populations.



NeuRA (Neuroscience Research Australia) is one of the largest independent medical and clinical research institutes in Australia and an international leader in neurological research.

Diseases of the brain and nervous system pose the greatest health, economic and social burden of any disease group because they are chronic, debilitating and have no known cures.

Medical research is the cornerstone of efforts to advance the health and wellbeing of families and the community. Our dedicated scientists are focussed on transforming their research into significant and practical benefits for all patients.

While we hope you find this information useful, it is always important to discuss any questions about schizophrenia or its treatment with your doctor or other health care provider.

For more information see the technical table

HOW YOUR SUPPORT HELPS

We are able to make significant advances due to the generosity of countless people. Your donation allows us to continue to work towards transforming lives. For information on how you can support our research, phone 1300 888 019 or make a secure donation at neura.edu.au/donate.